^
Association details:
| Biomarker: | MAP2K1 P124L |
|---|---|
| Cancer: | Melanoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Excerpt:
...examined two BRAF-mutant melanoma cell lines with endogenous MEK1P124Q (SMU030P) and MEK1P124L (D28; ref. 34) mutations... when compared with a small panel of BRAFV600/MEK1 wild-type melanoma cell lines, the SMU030P and D28 cell lines showed intermediate sensitivity to dabrafenib, but were exquisitely sensitive to the downstream MEK and ERK inhibitors, trametinib and VX-11e...
DOI:
10.1158/1078-0432.CCR-14-0759
